Les publications du Dr Roxane Paulin


  1. Bonnet S, Boucherat O, Paulin R, Wu D, Hindmarch CCT, Archer SL, Song R, Moore JB 4th, Provencher S, Zhang L, Uchida S. Clinical values of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases. Am J Physiol Cell Physiol. 2019 Sep 4.
  2. Nadeau V, Bonnet S, Paulin RLetter by Nadeau et al regarding article '' BMPR2 mutant rats develop pulmonary and cardiac characteristics of pulmonary arterial hypertension''. Circulation. 2019 Aug 13;140(7):e286-e287.
  3. Ranchoux B, Nadeau V, Bourgeois A, Provencher S, Tremblay É, Omura J, Coté N, Abu-Alhayja'a R, Dumais V, Nachbar RT, Tastet L, Dahou A, Breuils-Bonnet S, Marette A, Pibarot P, Dupuis J, Paulin R, Boucherat O, Archer SL, Bonnet S, Potus F. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease. Circ Res. 2019 Aug 2;125(4):449-466.
  4. Bourgeois A, Bonnet S, Breuils-Bonnet S, Habbout K, Paradis R, Tremblay E, Lampron MC, Orcholski ME, Potus F, Bertero T, Peterlini T, Chan SY, Norris KA, Paulin R, Provencher S, Boucherat O. Inhibition of CHK1 (Checkpoint kinase 1) elicits therapeutic effects in pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1667-1681.
  5.  Van der Feen DE, Kurakula K, Tremblay E, Boucherat O, Bossers GP, Szulcek R, Bourgeois A, Lampron MC, Habbout K, Martineau S, Paulin R, Kulikowski E, Jahagirdar R, Schalij I, Bogaard HJ, Bartelds B, Provencher S, Berger RMF, Bonnet S, Goumans MJ. Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2019 May 1
  6. Bonnet S, Paulin RInvolvement of PFKFB3 in pulmonary arterial hypertension pathogenesis. Is it all about glycolysis? Am J Respir Crit Care Med. 2019 Sep 1;200(5):532-534


  1. Bonnet S, Paulin R, Boucherat O. Small SeP or giant leap for Pulmonary Hypertension Research? Circulation. 2018 Aug 7;138(6):624-626
  2. Provencher S, Archer SL, Ramirez FD, Hibbert B, Paulin R, Boucherat O, Lacasse Y, Bonnet S. Standards and methodological rigor in pulmonary arterial hypertension preclinical and translational researchCirculation Research. 2018 Mar 30;122(7):1021-1032
  3. Brittain EL,Thenappan T,  Maron BA,  Chan SY, Austin ED, Spiekerkoetter E, Bogaard HJ, Guignabert C,  Paulin R, Machado RF,  Yu PB .Update in pulmonary vascular disease 2016 and 2017. Am J Respir Crit Care Med. 2018  Jul 1;198(1):13-23.
  4. Boucherat O, Peterlini T, Bourgeois A, Nadeau V, Breuils-Bonnet S, Boilet-Molez S, Potus F, Meloche J, Chabot S, Lambert C, Tremblay E, Chae YC, Altieri DC, Sutendra G, Michelakis ED, Paulin R, Provencher S, Bonnet S. Mitochondrial HSP90 accumulation promotes vascular remodeling in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2018 Jul 1;198(1):90-103.
  5. Nadeau V, Potus F, Boucherat O, Paradis R, Tremblay E, Iglarz M, Paulin R, Bonnet S, Provencher S. Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulmonary Circulation. 2018 Jan-Mar;8(1)


  1. Boucherat O, Chabot s, Paulin R, Trinh I, Bourgeois A, Potus F, Lampron MC, Lambert C, Breuils-Bonnet S, Nadeau V, Paradis R, Goncharova EA, Provencher S, Bonnet S. HDAC6: A novel histone deacetylase implicated in pulmonary arterial hypertension. Sci. Rep. 2017 Jul 3;7(1):4546
  2. Samson N, Paulin R. Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertensionPulm. Circ. 2017 Jun 19
  3. Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S. The cancer theory of pulmonary arterial hypertension. Pulm. Circ. 2017 Apr-Jun;7(2):285-289
  4. Meloche J, Lampron MC, Nadeau V, Maltais M, Potus F, Lambert C, Tremblay E, Vitry G, Breuils-Bonnet S, Boucherat O, Charbonneau E, Provencher S, Paulin R, Bonnet S. Implication of inflammation and epigenetics Readers in Coronary Artery Remodeling in patients with pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1513-1523. 


  1. Boucherat O, Bonnet S and Paulin RThe HIPPO-thesis of pulmonary HYPERtension. Am J Resp Crit Care Med. 2016 Oct 1;194(7):787-9
  2. Ranchoux B*, Meloche J*, Paulin R, Boucherat O, Provencher S, Bonnet S. DNA damage and pulmonary hypertension. International Journal of Molecular Sciences. 2016 Jun 22;17(6).
  3. Ruffenach*, Chabot S*, Tanguay VF, Courboulin A, Boucherat O, Potus f, Meloche J, Pflieger A, Breuils-Bonnet S, Nadeau V, Paradis R, Girerd B, Hautefort A, Montani D, Fadel E, Dorfmuller P, Humbert M, Perros F, Paulin R, Provencher S, Bonnet S. RUNX2 in proliferative and calcified vascular lesions seen in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2016 Nov15;194(10):1273-1285
  4. Kinnaird A, Dromparis P, Salee B, Gurtu V, Watson K, Paulin R, Zervopulos S, Stenson T, Sutendra G, Pink DB, Carmine-Simmen K, Moore R, Lewis JD, Michelakis ED. Metabolic Modulation od Clear-cell Renal cell carcinoma with Dicholoroacetate, an inhibitor of pyruvate dehydrogenase kinaseEur Urol. 2016 Apr;69(4):734-44


  1. Potus F, Ruffenach G, Dahou A, Thebault C, Breuils-Bonnet S, Tremblay È, Nadeau V, Paradis R, Graydon C, Wong R, Johnson I, Paulin R, Lajoie AC, Perron J, Charbonneau E, Joubert P, Pibarot P, Michelakis ED, Provencher S, Bonnet S. Downregulation of miR-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation. 2015 Sep 8;132(10):932-43.
  2. Paulin R, Michelakis ED. Addressing complexity in pulmonary hypertension: The FoxO1 case. Circ Res. 2015 May 22;116(11):1732-5
  3. Fillmore N, Huqi A, Jaswal JS, Mori J, Paulin R, Haromy A, Onay-Besikci A, Ionescu L, Thébaud B, Michelakis E, Lopaschuk GD. Effect of fatty acids on human bone marrow mesenchymal stem cell energy metabolism and survival. PLoS One. 2015 Mar 13;10(3):e0120257.
  4. Meloche J, Paulin R, Provencher S, Bonnet S. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension. Curr Vasc Pharmacol. 2015;13(3):331-40



  1. Paulin R, Dromparis P, Sutendra G, Gurtu V, Zervopoulos S, Bowers L, Haromy A, Webster L, Provencher SBonnet S, Michelakis ED. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humansCell Metab. 2014 Nov 4;20(5):827-39.
  2. Paulin R, Meloche J, Courboulin A, Lambert C, Haromy A, Courchesne A, Bonnet P, Provencher S, Michelakis ED, Bonnet STargeting cell motility in pulmonary arterial hypertension. Eur Respir J. 2014; 43(2): 531-44.
  3. Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A, Hashimoto K, Zhang N, Flaim E, Michelakis ED. A nuclear pyruvate dehydrogenase complex is important for the generation of actyl-CoA and histone acetylation. Cell. 2014 Jul 3;158(1):84-97.
  4. Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertensionCirc Res. 2014 Jun 20;115(1):148-64.
  5. Dromparis P, Sutendra G, Paulin R, Proctor S, Michelakis ED, McMurtry MS. Pioglitazone inhibits HIF-1α-dependent angiogenesis in rats by paracrine and direct effects on endothelial cellsJ Mol Med (Berl). 2014 May;92(5):497-507.
  6. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulous S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher SBonnet SRole for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014: 129(7): 786-97. 


  1. Malenfant S, Neyron AS, Paulin R, Potus F, Meloche J, Provencher S, Bonnet SSignal transduction pathways in the development of pulmonary arterial hypertensionPulm Circ. 2013 Apr;3(2):278-293.
  2. Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pivarot P, Bonnet S, Provencher S. Pim-1: a new biomarker in pulmonary arterial hypertension. Pulmonary Circulation 2013; 3(1): 74-81.
  3. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay E, Biardel S, Racine C, Couture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S.  Critical Role of the Advanced Glycation Endproducts Receptor in Pulmonary Arterial Hypertension Ethiology. J Am Heart Assoc 20132:e005157 doi: 10.1161/JAHA.112.00515
  4. Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J, Michelakis ED. A metebolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated sate in pulmonary hypertension. J Mol Med (Berl). 2013 Nov;91(11):1315-27
  5. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay E, Biardel S, Racine C, Couture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S.  Critical Role of the Advanced Glycation Endproducts Receptor in Pulmonary Arterial Hypertension Ethiology. J Am Heart Assoc 20132:e005157 doi: 10.1161/JAHA.112.00515 
  6. Dromparis P, Paulin R, Sutendra G, Qi AC, Bonnet S, Michelakis ED. Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary hypertensionCirc Res. 2013 Jul 5;113(2):126-36.
  7. Dromparis P, Paulin R, Stenson TH, Haromy A, Sutendra G, Michelakis ED. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation. 2013 Jan 1; 127(1):115-25




  1. Paulin R, Meloche J, Bonnet SSTAT3 signaling in pulmonary arterial hypertensionJAK-STAT 2012; 1(4): 1-11.
  2. Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, Paulin R, Tremblay E, Lambert C, Jacob MH, Bonnet SN, Provencher S, Bonnet S.  Plumbagin reverses proliferation and resistance to apoptosis in experimental PAHEur Respir J. 2012;40(3): 618-629.
  3. Paulin R, Michelakis ED. The estrogen puzzle in pulmonary arterial hypertensionCirculation. 2012 Aug 28;126(9):1016-9


  1. Courboulin A, Tremblay VL, Barrier M, Meloche J, Jacob MH, Chapolard M, Bisserier M, Paulin R, Lambert C, Provencher S, Bonnet SKrüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertensionRespir Res 2011; 12(1):128.
  2. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, Côté J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertensionCirculation. 2011;123(11):1205-15.
  3. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, Simard MJ, Bonnet SRole for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208(3):535-48.
  4. Meloche J, Paulin R, Courboulin A, Lambert C, Barrier M, Bonnet P, Bisserier M, Roy M, Sussman MA, Agharazii M, Bonnet S. RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2114-24

  5. Paulin R, Courboulin A, Barrier M, Bonnet S. From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. J Mol Med (Berl). 2011 Nov;89(11):1089-101

  6. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2011 Nov;301(5):H1798-809



  1. Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson KO, Nagendran J, Haromy A, Dyck JR, Michelakis ED. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axisCirculation 2009; 120(13):1231-40.
© 2012 Université Laval. Tous droits réservés